Business
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer.\n SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which is being held June 22 – 24, 2020. The poster is available for browsing on the AACR website from June 22 – 24, 2020. The poster presents findings from a preclinical study, conducted in collaboration with Dr. Arthur M. Mercurio and his lab at the University of Massachusetts Medical School, demonstrating that aTyr has generated a panel of anti-human NRP2 monoclonal antibodies that have the potential to be developed for the clinical management of solid tumors. Importantly, these antibodies showed differential binding to specific domains of NRP2, selectively inhibiting binding of either VEGF or Sema3F. In combination with chemotherapy, an antibody blocking the VEGF binding site of NRP2 was effective in preventing mammosphere formation in organoids derived from triple-negative breast cancer (TNBC) patients. Expression of NRP2 has been shown to be high in TNBC tumors and has been linked to worsened outcomes for patients. These results suggest that antibodies targeting NRP2 could potentially be effective in certain types of solid tumors, including breast cancer. Presentation Details: Title: Domain-Specific Antibodies to Neuropilin 2 Implicate VEGF-C and not Semaphorin 3F in Breast Cancer Stem Cell Function Authors: Leslie A. Nangle, Luke Burman, Hira L. Goel, Zhiwen Xu, Kristina Hamel, Nathaniel Bloom, Arthur M. Mercurio. aTyr Pharma, San Diego, CA, UMass Medical School, Boston, MA. Abstract Number: 7308 Session: Identification of Molecular Targets 1 Poster Number: 1785 Date and Time: June 22, 2020 (9:00AM – 6:00PM EDT) Following the virtual presentation, the poster will be available on the aTyr website. “I have been interested in understanding the role of Neuropilins in cancer for over 20 years and exploiting them as a therapeutic target for more aggressive cancers, such as triple-negative breast cance...